問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

E-DA Hospital (在職)

Division of Hematology & Oncology

E-DA Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

廖浚凱
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖浚凱

List

73Cases

2021-05-20 - 2023-05-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-20 - 2022-04-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2021-04-01 - 2022-09-30

Phase III

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia

  • Test Drug

    Rozanolixizumab

Participate Sites
8Sites

Not yet recruiting8Sites

2021-04-01 - 2029-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2016-03-31 - 2021-12-31

Phase III

A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

  • Condition/Disease

    Early Myelofibrosis

  • Test Drug

    JAKAVI

Participate Sites
3Sites

Terminated3Sites

2018-07-20 - 2021-02-12

Phase III

A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Rydapt

Participate Sites
4Sites

Terminated4Sites

2021-12-01 - 2029-05-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2015-04-01 - 2022-04-22

Phase III

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma (MM)

  • Test Drug

    Pomalidomide

Participate Sites
8Sites

Terminated7Sites

2017-05-16 - 2022-07-26

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

  • Condition/Disease

    Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Terminated5Sites

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

  • Condition/Disease

    neutropenic

  • Test Drug

    amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB